The First Hepatitis B “Functional Cure” Is Here. It Worked for About One in Five.

For decades, the central compromise in chronic hepatitis B treatment has been straightforward: existing antiviral drugs can suppress the virus extremely well, but they rarely eliminate the need for ongoing treatment.

On October 20, the FDA approved Hibsago, or bepirovirsen, for a narrowly defined group of adults with chronic hepatitis B. It is the first FDA-approved antisense oligonucleotide for the infection—and the first approved treatment shown to give some patients a realistic path to stopping all hepatitis B therapy while retaining viral control.

That is a meaningful change.

It is not, however, a universal cure. Across two large phase 3 trials, approximately one in five people receiving bepirovirsen met the researchers’ definition of a “functional cure.” Four in five did not.

The distinction matters, especially when a scientific term as powerful as cure enters ordinary conversation.

What the FDA actually approved

Hibsago is approved in combination with an existing nucleoside or nucleotide analogue antiviral—not as an immediate replacement for one.

Eligibility is unusually specific. The FDA indication covers certain adults who:

• Have chronic hepatitis B without cirrhosis
• Have received an existing hepatitis B antiviral for at least six months
• Have suppressed hepatitis B virus DNA
• Have a hepatitis B surface antigen, or HBsAg, level of 3,000 IU/mL or lower

The HBsAg measurement must be made with an FDA-authorized test. The FDA simultaneously authorized Roche’s Elecsys HBsAg II Quant II RxDx as a companion diagnostic for selecting and monitoring patients.

This is precision treatment in a fairly literal sense: a biomarker determines whether someone resembles the population in which the drug was shown to work.

The approved regimen lasts no more than 24 weeks. Patients continue their existing antiviral during treatment and for at least another 24 weeks afterward. Only patients meeting additional virologic and liver-test criteria can then be considered for stopping the older antiviral.

That sequence is important. The approval does not support simply substituting Hibsago for a daily antiviral or stopping established therapy independently.

What an antisense drug does

Bepirovirsen is a short, synthetic strand of genetic material designed to bind RNA produced by the hepatitis B virus.

That binding promotes degradation of viral RNA, reducing the instructions the virus uses to make proteins—including hepatitis B surface antigen. The drug also appears to stimulate parts of the innate immune response, although the contribution of that immune activity to its clinical effect is not fully understood.

Surface antigen is more than a marker of infection. Persistently high levels may help sustain the exhausted immune environment that allows chronic hepatitis B to continue. Lowering it substantially could give the immune system a better opportunity to regain control.

The underlying viral reservoir is not necessarily removed, however. Hepatitis B genetic material can persist within liver cells even when surface antigen becomes undetectable. That is why researchers use the term functional cure rather than sterilizing or complete cure.

The phase 3 results

The approval rests principally on the replicate B-Well 1 and B-Well 2 trials, published in The New England Journal of Medicine.

Together, the trials enrolled 1,834 adults with noncirrhotic chronic hepatitis B. All were already receiving stable nucleoside or nucleotide analogue therapy and had HBsAg levels above 100 but no higher than 3,000 IU/mL.

Participants were randomly assigned in a two-to-one ratio to receive bepirovirsen or placebo by subcutaneous injection for 24 weeks. Eligible participants discontinued their existing antiviral at week 48.

The primary endpoint was assessed at week 72: 24 weeks after eligible participants had stopped all hepatitis B therapy. A functional cure required both:

• Hepatitis B virus DNA below the assay’s lower limit of quantification
• Loss of detectable hepatitis B surface antigen

The results were remarkably consistent across the two trials:

• B-Well 1: 127 of 650 bepirovirsen recipients, or 20%, reached the endpoint, compared with 0 of 328 receiving placebo.
• B-Well 2: 106 of 570 bepirovirsen recipients, or 19%, reached the endpoint, compared with 0 of 286 receiving placebo.

Zero responses in the placebo groups make the drug’s biological effect difficult to dismiss. The near-identical findings in two separate trials also add confidence that the result was reproducible.

But the other side of the result deserves equal emphasis: roughly 80% of treated participants did not reach the functional-cure endpoint.

This is not a treatment that predictably frees most eligible patients from therapy. It creates that possibility for a meaningful minority.

Why 19% can still be a major advance

A result does not need to benefit most participants to change a field—particularly when the previous probability of achieving the same outcome was extremely low.

Current nucleoside and nucleotide analogue drugs can suppress hepatitis B replication, reduce liver inflammation, and lower the risk of cirrhosis and liver cancer. But surface-antigen loss remains uncommon, and treatment may continue for years or indefinitely.

Against that background, a roughly one-in-five chance of sustained control without treatment is clinically important.

The appeal is not merely avoiding a daily pill. Functional cure may reduce ongoing viral activity and the burden of lifelong treatment and monitoring. It may also signal a deeper degree of immune control.

What has not yet been established is whether a bepirovirsen-induced functional cure translates into fewer cases of cirrhosis, liver failure, liver cancer, or premature death over decades. The pivotal endpoint was a virologic and antigen endpoint measured 24 weeks after treatment withdrawal—not a long-term clinical outcome.

The trials therefore establish a new treatment state. They do not yet quantify its lifetime benefit.

The safety tradeoff is substantial

Bepirovirsen is not simply a six-month course with a modest chance of success and little downside.

In pooled phase 3 data, adverse events occurred in 91% of bepirovirsen recipients and 73% of placebo recipients. Serious adverse events occurred in 7% and 4%, respectively. During the 24-week treatment period, grade 3 or higher adverse events occurred in 16% of the bepirovirsen group and 3% of the placebo group.

Elevated alanine aminotransferase, or ALT, was the most frequent grade 3 event with bepirovirsen, occurring in 6% of treated participants. An ALT increase can reflect liver-cell injury, although some rises in these trials coincided with falling surface-antigen levels and may have represented an immune response against infected cells.

That ambiguity does not make the elevations benign. The FDA prescribing information carries a boxed warning for two risks:

• On-treatment hepatic flares
• Thrombocytopenia, or dangerously low platelet counts

The label says platelet reductions may be sudden, unpredictable, and potentially life-threatening. Two trial participants experienced serious thrombocytopenia below 50 billion platelets per liter, including one case of immune thrombocytopenia.

Kidney function also declined during treatment on average, although these changes were generally reversible after the drug was stopped. Four percent of treated participants had a sustained decline in estimated glomerular filtration rate exceeding 30% from baseline during the first 24 weeks.

Serious inflammatory and immune reactions were also reported, including autoimmune hemolytic anemia, systemic inflammatory response syndrome, and a cryoglobulinemic flare.

The monitoring requirements reflect these risks. Liver tests and platelets are checked frequently, with platelet monitoring required at least weekly during treatment. Kidney function is monitored at least every other week. Abnormal results can require dose reduction, interruption, or permanent discontinuation.

This is a finite treatment, but not a light-touch one.

The eligible population is narrower than the headline

The phrase “first functional cure for hepatitis B” may create the impression of a treatment broadly available to anyone with the infection. The approved population is much smaller.

The trials did not establish safety or effectiveness for people with cirrhosis, and the drug is contraindicated in patients with acute hepatic impairment or cirrhosis accompanied by hepatic impairment. People with moderate or severe kidney impairment were excluded from the trials, leaving limited safety information for that group.

The treatment also requires an HBsAg level no higher than 3,000 IU/mL at baseline, suppressed viral DNA, and prior stable antiviral therapy.

Even among people who start the treatment, stopping the established antiviral is conditional. Under the FDA label, patients must complete Hibsago treatment, remain on the existing antiviral for at least another 24 weeks, and then meet criteria including undetectable HBsAg, very low HBV DNA, acceptable ALT levels, and negative hepatitis B e-antigen status.

Frequent monitoring is recommended for at least a year after antiviral withdrawal.

The practical pathway is therefore closer to:

careful selection → six months of combination treatment → six more months of assessment → possible antiviral withdrawal → continued surveillance

It is not a short course followed by a declaration that the infection is gone.

What the approval does—and does not—prove

The approval supports several firm conclusions:

• Antisense treatment can produce treatment-free functional cure in some carefully selected adults with chronic hepatitis B.
• The effect was reproduced in two randomized, placebo-controlled phase 3 trials.
• A fixed-duration treatment can move approximately one in five eligible patients into a state that existing suppressive therapy rarely achieves.
• The treatment has meaningful toxicity and requires close laboratory supervision.

Several larger questions remain open:

• How durable will functional cure be after several years rather than 24 weeks?
• Will it reduce liver cancer, cirrhosis, and mortality beyond the protection already provided by viral suppression?
• Can researchers identify more precisely who is likely to respond before treatment begins?
• Can combination strategies raise response rates without adding unacceptable risk?
• How will cost, access to the companion test, and the monitoring burden affect real-world use?

Those questions do not negate the advance. They define its current boundaries.

Practical takeaways

This is a real FDA approval, not an experimental longevity intervention. Hibsago is approved for a specific chronic infection in a defined patient population.

“Functional cure” is a technical endpoint. It means sustained viral control plus loss of detectable surface antigen after treatment withdrawal. It does not prove that every trace of the virus has been eliminated.

The headline number is about one in five. That is a major improvement over placebo and over the rarity of functional cure with existing suppressive treatment—but it is not a majority response.

The tradeoff includes intensive monitoring and potentially serious adverse effects. Liver flares, low platelets, kidney changes, and inflammatory reactions make patient selection and follow-up central to the treatment, not incidental details.

Existing hepatitis B therapy should not be stopped based on a news report or a single laboratory result. In the approved pathway, withdrawal is considered only after treatment, additional antiviral therapy, predefined laboratory milestones, and clinician-supervised monitoring.

The Modern Bio take

Hibsago is a useful example of what precision medicine looks like when the marketing language is stripped away.

The drug targets a specific viral molecule. A quantitative biomarker helps identify eligible patients. Two large randomized trials show a reproducible effect. And the outcome is meaningful—but limited: approximately 20% achieved treatment-free functional cure, approximately 80% did not, and everyone accepted a nontrivial monitoring and safety burden.

That is neither a miracle nor a disappointment. It is a genuine step forward with well-defined edges.

The next scientific challenge is not to celebrate the word cure. It is to learn how durable the response is, who is most likely to achieve it, and whether that laboratory and virologic success becomes fewer cases of liver cancer and liver failure over time.

Sources

• U.S. Food and Drug Administration. FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment. October 20, 2026.
• Yuen MF, et al. Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection. New England Journal of Medicine. 2026;394:2395–2406. DOI: 10.1056/NEJMoa2515131.
• PubMed record and abstract. PMID: 42206582.
• U.S. Food and Drug Administration. Hibsago prescribing information. October 2026.
• ClinicalTrials.gov: B-Well 1, NCT05630807 and B-Well 2, NCT05630820.

A clearer next step

For a weekly, evidence-first look at important developments in health, medicine, and longevity, get the free Modern Bio Brief.